Vilon: A Khavinson Dipeptide Bioregulator (Lys-Glu)

Research summary. Vilon is a short dipeptide (Lys-Glu; KE) developed within the Khavinson "peptide bioregulator" research programme in St. Petersburg, Russia. It is among the smallest peptides reported to have biological activity in that framework. Within the originating programme, Vilon has been described as immunomodulatory — reportedly acting on thymic and splenic lymphocyte populations — with additional reports of geroprotective, chromatin-decondensing, and tumour-suppressive effects in rodent models. As with the wider Khavinson bioregulator family, the supporting literature is concentrated within the originating Russian research programme, and independent Western validation of the underlying mechanistic model is limited. Researchers should treat reported effects as hypothesis-generating.

Molecular profile

• Sequence: Lys-Glu (KE; H-Lys-Glu-OH)
• Molecular formula: C₁₁H₂₁N₃O₅
• Molecular weight: ~275.3 g/mol
• PubChem CID: 7010502
• CAS number: 45234-02-4
• Class: Khavinson short-chain peptide bioregulator (cytomedine family)
• Reported tissue tropism: Thymic and immune tissue

Mechanism of action

The mechanistic framework proposed within the Khavinson research programme for Vilon emphasises:

• Chromatin-state modulation. Reports from the programme describe Vilon-associated decondensation of euchromatin and reactivation of ribosomal genes in lymphocyte nuclei, framed as an "anti-aging" effect on chromatin organisation.
• Tissue-specific transcriptional effects. Vilon has been reported to modulate expression of immune-related genes including those in the IL-2 signalling pathway.
• Reported effects on lymphocyte subsets. Programme reports describe effects on CD5⁺, CD4⁺ helper, and CD8⁺ cytotoxic T-cell populations in thymic and splenic tissue.
• Limited independent characterisation. As with the wider Khavinson bioregulator class, the standard pharmacology framework (receptor identification, structure–activity relationships, independent in vitro reproductions) is not well established outside the originating programme.

Preclinical research highlights

Immunomodulation. Within the Khavinson programme, Vilon has been reported to modulate lymphocyte function and IL-2-related signalling in rodent and cell-culture studies.

Chromatin and gene reactivation. A characteristic mechanistic claim associated with Vilon is the reported decondensation of euchromatin and reactivation of silenced ribosomal genes — proposed as a counter to age-related chromatin condensation in lymphoid tissue.

Tumour incidence in mice. Reports from the programme, associated with Anisimov and colleagues, describe reduced spontaneous-tumour incidence in mice receiving Vilon. The role of the peptide as a complement to active oncology treatment, however, is not established.

Geroprotective endpoints. Reported effects on lifespan, locomotor activity, and gastrointestinal-enzyme function in aged rodents are also described within the same programme.

Independent validation. Independent Western preclinical replication of these specific findings is limited, and the broad scope of claimed effects across diverse organ systems should be evaluated against the depth and replication of the supporting literature.

Current research status

Vilon is not approved by any major Western regulator (FDA, EMA, MHRA) for any indication. It is supplied as a research-grade peptide where available and is not intended for self-administration. Researchers working with this peptide should approach it as an investigational research material, recognise the limited independent literature, and design experiments with appropriate vehicle controls and orthogonal endpoints.

Key takeaways for researchers

• Vilon is a Lys-Glu (KE) dipeptide and one of the smallest peptides reported to have biological activity within the Khavinson bioregulator framework.
• Within that framework, it is described as immunomodulatory, chromatin-decondensing, and geroprotective in rodent models.
• Supporting literature is concentrated in the originating Russian research programme; independent Western validation of the underlying mechanistic model is limited.
• It is not FDA-approved and is supplied as a research-grade peptide for laboratory use only.

References

1. Khavinson VK, Linkova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2014;156(6):737–743.
2. Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139–149.

---

This article is provided for educational and research purposes only. Vilon is a research peptide. It is not currently FDA-approved and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. The supporting literature is concentrated in a single research programme and independent validation is limited. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.